The hallmarks of cancer

Cell

Volumn 100, Issue 1, 2000, Pages 57-70

  Hanahan, Douglas ^a   Weinberg, Robert A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; APOPTOSIS; CANCER; CANCER GROWTH; CARCINOGENESIS; CELL DIVISION; CELL INVASION; GENOME; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0034614637     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81683-9     Document Type: Review

References (102)

1. Aplin, A.E., Howe, A., Alahari, S.K., and Juliano, R.L. (1998). Signal transduction and signal modulation by cell adhesion receptors: The role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 50, 197-263.
2. Ashkenazi, A., and Dixit, V.M. (1999). Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11, 255-260.
3. Bergers, G., and Coussens, L.M. (2000). Extrinsic regulators of epithelial tumor progression: Metalloproteinases. Curr. Opin. Genet. Dev., in press.
4. Bergers, G., Hanahan, D., and Coussens, L.M. (1998). Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int. J. Dev. Biol. 42, 995-1002.
5. Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan, D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812.
6. Bishop, J.M., and Weinberg, R.A., eds. (1996). Molecular Oncology (New York: Scientific American, Inc.).
7. Bodnar, A.G., Ouellete, M., Frolkis, M., Holt, S.E., Chiu, C., Morin, G.B., Harley, C.B., Shay, J.W., Lichtsteiner, S., and Wright, W.E. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352.
8. Bouck, N., Stellmach, V., and Hsu, S.C. (1996). How tumors become angiogenic. Adv. Cancer Res. 69, 135-174.
9. Bryan, T.M., and Cech, T.R. (1999). Telomerase and the maintenance of chromosome ends. Curr. Opin. Cell Biol. 11, 318-324.
10. Bryan, T.M., Englezou, A., Gupta, J., Bacchetti, S., and Reddel, R.R. (1995). Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 14, 4240-4248.
11. Bull, H.A., Brickell, P.M., and Dowd, P.M. (1994). Src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells. FEBS Lett. 351, 41-44.
12. Butt, A.J., Firth, S.M., and Baxter, R.C. (1999). The IGF axis and programmed cell death. Immunol. Cell Biol. 77, 256-262.
13. Cantley, L.C., and Neel, B.C. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96, 4240-4245.
14. Chambers, A.F., and Matrisian, L.M. (1997). Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89, 1260-1270.
15. Chin, L., Pomerantz, J., and Depinho, R.A. (1998). The INK4a/ARF tumor suppressor: One gene - Two products - Two pathways. Trends Biochem. Sci. 23, 291-296.
16. Christofori, G., and Semb, H. (1999). The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci. 24, 73-76.
17. Christofori, G., Naik, P., and Hanahan, D. (1994). A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369, 414-418.
18. Cordon-Cardo, C., and Prives, C. (1999). At the crossroads of inflammation and tumorigenesis. J. Exp. Med. 190, 1367-1370.
19. Counter, C.M., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W., Harley, C.B., and Bacchetti, S. (1992). Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921-1929.
20. Counter, C.M., Hahn, W.C., Wei, W., Dickinson Caddle, S., Beijersbergen, R.L., Lansdorp, P.M., Sedivy, J.M., and Weinberg, R.A. (1998). Dissociation between telomerase activity, telomere maintenance and cellular immortalization. Proc. Natl. Acad. Sci. USA 95, 14723-14728.
21. Coussens, L.M., and Werb, Z. (1996). Matrix metalloproteinases and the development of cancer. Chem. Biol. 3, 895-904.
22. Coussens, L.M., Raymond, W.W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G.H., and Hanahan, D. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13, 1382-1397.
23. Dameron, K.M., Volpert, O.V., Tainsky, M.A., and Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584.
24. Datto, M.B., Hu, P.P., Kowalik, T.F., Yingling, J., and Wang, X.F. (1997). The viral oncoprotein E1A blocks transforming growth factor β-mediated induction of p21/WAF1/Cip1 and p15/INK4B Mol. Cell. Biol. 17, 2030-2037.
25. DiFiore, P.P., Pierce, J.H., Kraus, M.H., Segatto, O., King, C.R., and Aaronson, S.A. (1987). Erbb-2 is a potent oncogene when overex-pressed in NIH/3T3 cells. Science 237, 178-182.
26. Downward, J. (1998). Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10, 262-267.
27. Dyson, N., Howley, P.M., Munger, K., and Harlow, E. (1989). The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-937.
28. Evan, G., and Littlewood, T. (1998). A matter of life and cell death. Science 281, 1317-1322.
29. Fedi, P., Tronick, S.R., and Aaronson, S.A. (1997). Growth factors. In Cancer Medicine, J.F. Holland, R.C. Bast, D.L. Morton, E. Frei, D.W. Kufe, and R.R. Weichselbaum, eds. (Baltimore, MD: Williams and Wilkins), pp. 41-64.
30. Fogar, P., Basso, D., Pasquali, C., De Paoli, C., Sperti, C., Roveroni, G., Pedrazzoli, G., and Plebani, M. (1997). Neural cell adhesion molecule (N-CAM) in gastrointestinal neoplasias. Anticancer Res. 17, 1227-1230.
31. Foley, K.P., and Eisenman, R.N. (1999). Two MAD tails: What the recent knockouts of Mad1 and Mx1 tell us about the MYC/MAX/ MAD network. Biochim. Biophys. Acta 1423, M37-47.
32. Folkman, J. (1997). Tumor angiogenesis. In Cancer Medicine, J.F. Holland, R.C. Bast, D.L. Morton, E. Frei, D.W. Kufe, and R.R. Weichselbaum, eds. (Baltimore, MD: Williams and Wilkins), pp. 181-204.
33. Foulds, L. (1954). The Experimental Study of Tumor Progression. Volumes I-III (London: Academic Press).
34. Fynan, T.M., and Reiss, M. (1993). Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit. Rev. Oncog. 4, 493-540.
35. Gately, S., Twardowski, P., Stack, M.S., Cundiff, D.L., Grella, D., Castellino, F.J., Enghild, J., Kwaan, H.C., Lee, F., Kramer, R.A., et al. (1997). The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA 94, 10868-10872.
36. Giancotti, F.G., and Ruoslahti, E. (1999). Integrin signaling. Science 285, 1028-1032.
37. Green, D.R., and Reed, J.C. (1998). Mitochondria and apoptosis. Science 281, 1309-1312.
38. 2/3 cancer-prone mouse. Cell 97, 515-525.
39. Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbgern, R.L., Brooks, M.W., and Weinberg, R.A. (1999). Creation of human tumor cells with defined genetic elements. Nature 400, 464-468.
40. Halvorsen, T.L., Leibowitz, G., and Levine, F. (1999). Telomerase activity is sufficient to allow transformed cells to escape from crisis. Mol. Cell. Biol. 19, 1864-1870.
41. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
42. INK4b is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371, 257-261.
43. Harris, C.C. (1996). P53 tumor suppressor gene: From the basic research laboratory to the clinic - An abridged historical perspective. Carcinogenesis 17, 1187-1198.
44. Hayflick, L. (1997). Mortality and immortality at the cellular level. A review. Biochemistry 62, 1180-1190.
45. Holmgren, L., Szeles, A., Rajnavolgyi, E., Folkman, J., Klein, G., Ernberg, I., and Falk, K.I. (1999). Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood 93, 3956-3963.
46. Hudson, J.D., Shoaibi, M.A., Maestro, R., Carnero, A., Hannon, G.J., and Beach, D.H. (1999). A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190, 1375-1382.
47. Hueber, A.O., Zornig, M., Lyon, D., Suda, T., Nagata, S., and Evan, G.I. (1997). Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278, 1305-1309.
48. Hunter, T. (1997). Oncoprotein networks. Cell 88, 333-346.
49. Hynes, R.O., and Wagner, D.D. (1996). Genetic manipulation of vascular adhesion molecules in mice. J. Clin. Invest. 98, 2193-2195.
50. Ishizaki, Y., Cheng, L., Mudge, A.W., and Raff, M.C. (1995). Programmed cell death by default in embryonic cells, fibroblasts, and cancer cells. Mol. Biol. Cell 6, 1443-1458.
51. Johnsen, M., Lund, L.R., Romer, J., Almholt, K., and Dano K. (1998). Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol. 10, 667-671.
52. Johnson, J.P. (1991). Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Metastasis Rev. 10, 11-22.
53. Kahn, P., Frykberg, L., Brady, C., Stanley, I., Beug, H., Vennström, B., and Graf, T. (1986). V-erbA cooperates with sarcoma oncogenes in leukemic cell transformation. Cell 45, 349-356.
54. Kaiser, U., Auerbach, B., and Oldenburg, M. (1996). The neural cell adhesion molecule NCAM in multiple myeloma. Leuk. Lymphoma 20, 389-395.
55. Kerr, J.F., Wyllie, A.H., and Currie, A.R. (1972). Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257.
56. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Philipps, H.S., and Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
57. Kinzler, K.W., and Vogelstein, B. (1996). Lessons from hereditary colorectal cancer. Cell 87, 159-170.
58. Kinzler, K.W., and Vogelstein, B. (1998). Landscaping the cancer terrain. Science 280, 1036-1037.
59. Korsmeyer, S.J. (1992). Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu. Rev. Immunol. 10, 785-807.
60. Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1998). Genetic instabilities in human cancers. Nature 396, 643-649.
61. Levine, A.J. (1997). P53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
62. Loeb, L.A. (1991). Mutator phenotype may be required for multistep carcinogenesis. Cancer Res. 51, 3073-3079.
63. Lotem, J., and Sachs, L. (1996). Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia 10, 925-931.
64. Lukashev, M.E., and Werb, Z. (1998). ECM signaling: Orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8, 437-441.
65. Markowitz, S., Wang, J., Meyeroff, L., Parsons, R., Sun, L., LutterBaugh, J., Fan, R., Zborowska, E., Kinzler, K., Vogelstein, B., et al. (1995). Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338.
66. Maxwell, P.H., Wiesener, M.S., Chang, G.-W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275.
67. McDonnell, T.J., and Korsmeyer, S.J. (1991). Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349, 254-256.
68. Medema, R.H., and Bos, J.L. (1993). The role of p21-ras in receptor tyrosine kinase signaling. Crit. Rev. Oncog. 4, 615-661.
69. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
70. Moses, H.L., Yang, E.Y., and Pietenpol, J.A. (1990). TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights. Cell 63, 245-247.
71. Nowell, P.C. (1976). The clonal evolution of tumor cell populations. Science 194, 23-28.
72. Olumi, A.F., Grossfeld, G.D., Hayward, S.W., Carroll, P.R., TIsty, T.D., and Cunha, G.R. (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011.
73. Perl, A.-K., Dahl, U., Wilgenbus, P., Cremer, H., Semb, H., and Christofori, G. (1999). Reduced expresion of neural cell adhesion molecule induces metastatic dissemination of pancreatic β tumor cells. Nat. Med. 5, 286-291.
74. Pitti, R.M., Marsters, S.A., Lawrence, D.A., Roy, M., Kischkel, F.C., Dowd, P., Huang, A., Donahue, C.J., Sherwood, S.W., Baldwin, D.T., et al. (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699-703.
75. Rak, J., Filmus, J., Finkenzeller, G., Grugel, S., Marme, D., and Kerbel, R.S. (1995). Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14, 263-277.
76. Renan, M.J. (1993). How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinogenesis 7, 139-146.
77. Rommel, C., and Hafen, E. (1998). Ras - A versatile cellular switch. Curr. Opin. Genet. Dev. 8, 412-418.
78. Schutte, M., Hruban, R., Hedrick, L., Cho, K., Nadasdy, G., Weinstein, C., Bova, G., Isaacs, W., Cairns, P., Nawroz, H., et al. (1996). DPC4 gene in various tumor types. Cancer Res. 56, 2527-2530.
79. INK4a. Cell 88, 593-602.
80. Shibata, M.A., Maroulakou, I.G., Jorcyk, C.L., Gold, L.G., Ward, J.M., and Green, J.E. (1996). P53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: Suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res. 56, 2998-3003.
81. Shay, J.W., and Bacchetti, S. (1997). A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787-791.
82. Singh, R.K., Gutman, M., Bucana, C.D., Sanchez, R., Llansa, N., and Fidler, I.J. (1995). Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA 92, 4562-4566.
83. Skobe, M., and Fusenig, N.E. (1998). Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl. Acad. Sci. USA 95, 1050-1055.
84. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
85. Sporn, M.B. (1996). The war on cancer. Lancet 347, 1377-1381.
86. Stetler-Stevenson, W.G. (1999). Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J. Clin. Invest. 103, 1237-1241.
87. Strasser, A., Harris, A.W., Bath, M.L., and Cory, S. (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331-333.
88. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. (1994). P53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711.
89. Thornberry, N.A., and Lazebnik, Y. (1998). Caspases: Enemies within. Science 281, 1312-1316.
90. Varner, J.A., and Cheresh, D.A. (1996). Integrins and cancer. Curr. Opin. Cell Biol. 8, 724-730.
91. Vaux, D.L., Cory, S., and Adams, T.M. (1988). Bcl-2 promotes the survival of hematopoietic cells and cooperates with c-mycto immortalize pre-B cells. Nature 335, 440-442.
92. Vaziri, H., and Benchimol, S. (1998). Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8, 279-282.
93. Veikkola, T., and Alitalo, K. (1999). VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 9, 211-220.
94. Volpert, O.V., Dameron, K.M., and Bouck, N. (1997). Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14, 1495-1502.
95. Weinberg, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
96. Werb, Z. (1997). ECM and cell surface proteolysis: Regulating cellular ecology. Cell 91, 439-442.
97. Whitelock, J.M., Murdoch, A.D., Iozzo, R.V., and Underwood, P.A. (1996). The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 271,10079-10086.
98. Wright, W.E., Pereira-Smith, O.M., and Shay, J.W. (1989). Reversible cellular senescence: Implications for immortalization of normal human diploid fibroblasts. Mol. Cell. Biol. 9, 3088-3092.
99. Wyllie, A.M., Kerr, J.F., and Currie, A.R. (1980). Cell death: The significance of apoptosis. Int. Rev. Cytol. 68, 251-306.
100. Yarden, Y., and Ullrich, A. (1988). EGF and erbB2 receptor overexpression in human tumors. Growth factor recepor tyrosine kinases. Annu. Rev. Biochem. 57, 443-478.
101. Zhu, J., Wang, H., Bishop, J.M., and Blackburn, E.H. (1999). Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc. Natl. Acad. Sci. USA 96, 3723-3728.
102. INK4A binding domain of CDK4 in familial melanoma. Nat. Genet. 12, 97-99.